Teva’s citizen petition to the FDA on behalf of MSers in the USA

T
In response to an email request about not being able to access the following letter online. I have downloaded it for you and embedded the full letter for you to read.




The following is the result of our survey in relation to this letter:

Other posts in relation to Teva on this blog:
17 Jan 2013
As you know TEVA has requested that licensing of new drugs are delayed until the safety of any new drug is adequately reviewed, with an effect of trying to delay BG-12 and Lemtrada, although they are clearly aiming at the 
13 Jan 2013
“Teva,the producer of glatiramer acetate, has asked the FDA not to approve BG-12, citing safety concerns. Teva filed a citizen’s petition requesting that the FDA refrain from approving any new drug for the treatment of MS until 
07 Apr 2012
Teva Pharmaceutical Industries Ltd. (TEVA) sued Synthon BV for infringing seven patents in planning to sell a generic version of the multiple sclerosis drug Copaxone before Teva’s patents expire. Teva, based in Petach Tikva, 
04 Nov 2011
Laquinimod News. After the phase 3 results (Allegro and Bravo studies) Teva’s CEO Shlomo Yanai made the following statement concerning laquinimod: “Teva has held a meeting with the Food and Drug Administration (FDA) 

About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.

8 comments

By Prof G

Translate

Categories

Recent Posts

Recent Comments

Archives